Home

Nitroxyl Technology

Cardioxyl has developed industry leading expertise in nitroxyl (HNO) chemistry and biology, and is employing its nitroxyl chemistry platform to discover and develop novel, proprietary therapeutics targeting cardiovascular disease.
Read More

CXL-1020

CXL-1020, a proprietary compound generated by Cardioxyl's nitroxyl chemistry platform, has recently completed a Phase IIa clinical trial in acute decompensated heart failure.
Read More

News

08.26.10 Cardioxyl Pharmaceuticals Initiates Dose-Defining Phase IIA Study of Its Lead Candidate, CXL-1020, in Heart Failure Patients

08.02.10 Cardioxyl Pharmaceuticals Announces Positive Results from First Clinical Study of its Lead Therapy, CXL-1020, in Heart Failure Patients

04.01.10 Cardioxyl Pharmaceuticals' Data Presented at American College of Cardiology (ACC) Annual Scientific Sessions

11.18.09 Cardioxyl Pharmaceuticals Announces Pre-Clinical Results on Lead Clinical Candidate, CXL-1020

10.29.09 Cardioxyl Pharmaceuticals Announces Late-Breaker at American Heart Association Conference